NASDAQ · AKYA
Healthcare · Medical - Instruments & Supplies
$1.29
Down-$0.07 (-5.15%)
Updated Aug 22, 2026, 8:33 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
AKYA does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning AKYA.
AKYA research
Company profile and research snapshot.
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 19, 2025 | Canaccord Genuity | Hold | — |
| Apr 29, 2025 | Canaccord Genuity | Hold | — |
| Apr 14, 2025 | Piper Sandler | Neutral | — |
| Mar 25, 2025 | Stephens & Co. | Equal-Weight | — |
| Mar 18, 2025 | Stephens & Co. | Overweight | — |
No generated briefing is available yet.
Benzinga · Apr 23, 2025
The M&A Class Action Firm is investigating the proposed mergers of Global Blue Group Holding, Yotta Acquisition Corporation, Southport Acquisition Corporation, and Akoya Biosciences with other companies. The firm encourages shareholders to act on these mergers.
GlobeNewswire Inc. · Jan 11, 2025
Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed sales of Shutterstock, Accolade, ESSA Bancorp, and Akoya Biosciences.
GlobeNewswire Inc. · Nov 14, 2024
Akoya Biosciences reported lower-than-expected Q3 2024 revenue due to ongoing capital equipment purchase constraints in the life science tools market. The company remains optimistic about long-term growth and is implementing organizational restructuring to address the current challenges.
GlobeNewswire Inc. · Oct 3, 2024
Akoya Biosciences, Inc. announced that Scott Mendel has been appointed as the new Chairman of its Board, succeeding Robert Shepler, the founding Chairman. Mendel has over 30 years of financial and operational management experience and is expected to leverage his public company experience to assist in delivering on Akoya's potential and maximizing shareholder return.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AKYA.
No results
No recent SID articles mention AKYA.
